APO RESEARCH · REPORT
Darbepoetin Alfa
Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
Product & engineering
Understand the product.
Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
Selected research
Industry Research
Darbepoetin Alfa Industry Research Report 2026
Market perspective
Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
The classification of Darbepoetin Alfa includes Epogen, Procrit, Aranesp and others, and the proportion of Epogen in 2017 is about 45%.
Darbepoetin Alfa is widely used for Patients with Chronic Kidney Disease, Patients with Cancer others. The most proportion of Darbepoetin Alfa is used for the Patients with Chronic Kidney Disease, and the proportion in 2017 is 62%.
Read the full market overview
North America is the largest consumption place, with a consumption market share nearly 47% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 41%.
Market competition is not intense. Amgen, Johnson & Johnson, Kyowa Hakko Kirin, Novartis and 3SBio etc. are the leaders of the industry, with about 87% market shares.
Report Scope
This report quantifies the global Darbepoetin Alfa market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Darbepoetin Alfa Market by Company
Amgen
Johnson & Johnson
Kyowa Hakko Kirin
Novartis
3SBio
Darbepoetin Alfa Segment by Type
Epogen
Procrit
Aranesp
Others
Darbepoetin Alfa Segment by Application
Patients with Chronic Kidney Disease
Patients with Cancer
Others
Darbepoetin Alfa Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Darbepoetin Alfa market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Darbepoetin Alfa and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Darbepoetin Alfa.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Darbepoetin Alfa manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Darbepoetin Alfa by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Darbepoetin Alfa in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Epogen
- Procrit
- Aranesp
- Others
Applications
- Patients with Chronic Kidney Disease
- Patients with Cancer
- Others
Companies covered
- Amgen
- Johnson & Johnson
- Kyowa Hakko Kirin
- Novartis
- 3SBio
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Darbepoetin Alfa Market Size (2021-2032)
- 2.2.2 Global Darbepoetin Alfa Sales (2021-2032)
- 2.2.3 Global Darbepoetin Alfa Market Average Price (2021-2032)
- 2.3 Darbepoetin Alfa by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Epogen
- 2.3.3 Procrit
- 2.3.4 Aranesp
- 2.3.5 Others
- 2.4 Darbepoetin Alfa by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Patients with Chronic Kidney Disease
- 2.4.3 Patients with Cancer
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Darbepoetin Alfa Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Darbepoetin Alfa Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Darbepoetin Alfa Revenue of Manufacturers (2021-2026)
- 3.4 Global Darbepoetin Alfa Average Price by Manufacturers (2021-2026)
- 3.5 Global Darbepoetin Alfa Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Darbepoetin Alfa, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Darbepoetin Alfa, Product Type & Application
- 3.8 Global Manufacturers of Darbepoetin Alfa, Established Date
- 3.9 Global Darbepoetin Alfa Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Amgen
- 4.1.1 Amgen Company Information
- 4.1.2 Amgen Business Overview
- 4.1.3 Amgen Darbepoetin Alfa Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Amgen Darbepoetin Alfa Product Portfolio
- 4.1.5 Amgen Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Darbepoetin Alfa Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Darbepoetin Alfa Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Kyowa Hakko Kirin
- 4.3.1 Kyowa Hakko Kirin Company Information
- 4.3.2 Kyowa Hakko Kirin Business Overview
- 4.3.3 Kyowa Hakko Kirin Darbepoetin Alfa Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Kyowa Hakko Kirin Darbepoetin Alfa Product Portfolio
- 4.3.5 Kyowa Hakko Kirin Recent Developments
- 4.4 Novartis
- 4.4.1 Novartis Company Information
- 4.4.2 Novartis Business Overview
- 4.4.3 Novartis Darbepoetin Alfa Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Novartis Darbepoetin Alfa Product Portfolio
- 4.4.5 Novartis Recent Developments
- 4.5 3SBio
- 4.5.1 3SBio Company Information
- 4.5.2 3SBio Business Overview
- 4.5.3 3SBio Darbepoetin Alfa Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 3SBio Darbepoetin Alfa Product Portfolio
- 4.5.5 3SBio Recent Developments
5 Global Darbepoetin Alfa Market Scenario by Region
- 5.1 Global Darbepoetin Alfa Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Darbepoetin Alfa Sales by Region: 2021-2032
- 5.2.1 Global Darbepoetin Alfa Sales by Region: 2021-2026
- 5.2.2 Global Darbepoetin Alfa Sales by Region: 2027-2032
- 5.3 Global Darbepoetin Alfa Revenue by Region: 2021-2032
- 5.3.1 Global Darbepoetin Alfa Revenue by Region: 2021-2026
- 5.3.2 Global Darbepoetin Alfa Revenue by Region: 2027-2032
- 5.4 North America Darbepoetin Alfa Market Facts & Figures by Country
- 5.4.1 North America Darbepoetin Alfa Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Darbepoetin Alfa Sales by Country (2021-2032)
- 5.4.3 North America Darbepoetin Alfa Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Darbepoetin Alfa Market Facts & Figures by Country
- 5.5.1 Europe Darbepoetin Alfa Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Darbepoetin Alfa Sales by Country (2021-2032)
- 5.5.3 Europe Darbepoetin Alfa Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Darbepoetin Alfa Market Facts & Figures by Country
- 5.6.1 Asia Pacific Darbepoetin Alfa Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Darbepoetin Alfa Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Darbepoetin Alfa Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Darbepoetin Alfa Market Facts & Figures by Country
- 5.7.1 South America Darbepoetin Alfa Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Darbepoetin Alfa Sales by Country (2021-2032)
- 5.7.3 South America Darbepoetin Alfa Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Darbepoetin Alfa Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Darbepoetin Alfa Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Darbepoetin Alfa Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Darbepoetin Alfa Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Darbepoetin Alfa Sales by Type (2021-2032)
- 6.1.1 Global Darbepoetin Alfa Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Darbepoetin Alfa Sales Market Share by Type (2021-2032)
- 6.2 Global Darbepoetin Alfa Revenue by Type (2021-2032)
- 6.2.1 Global Darbepoetin Alfa Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Darbepoetin Alfa Revenue Market Share by Type (2021-2032)
- 6.3 Global Darbepoetin Alfa Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Darbepoetin Alfa Sales by Application (2021-2032)
- 7.1.1 Global Darbepoetin Alfa Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Darbepoetin Alfa Sales Market Share by Application (2021-2032)
- 7.2 Global Darbepoetin Alfa Revenue by Application (2021-2032)
- 7.2.1 Global Darbepoetin Alfa Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Darbepoetin Alfa Revenue Market Share by Application (2021-2032)
- 7.3 Global Darbepoetin Alfa Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Darbepoetin Alfa Value Chain Analysis
- 8.1.1 Darbepoetin Alfa Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Darbepoetin Alfa Production Mode & Process
- 8.2 Darbepoetin Alfa Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Darbepoetin Alfa Distributors
- 8.2.3 Darbepoetin Alfa Customers
9 Global Darbepoetin Alfa Analyzing Market Dynamics
- 9.1 Darbepoetin Alfa Industry Trends
- 9.2 Darbepoetin Alfa Industry Drivers
- 9.3 Darbepoetin Alfa Industry Opportunities and Challenges
- 9.4 Darbepoetin Alfa Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst